SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy

SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy
SOTIO has enrolled its first ovarian cancer patient in a Phase 2 clinical trial evaluating its immunotherapy DCVAC/OvCa. The SOV06 trial will look at the therapy’s effectiveness as an add-on to standard chemotherapy in women who responded to first-line platinum-based chemo but eventually relapsed. The standard chemotherapies will be two Bristol-Myers Squibb products, Paraplatin (carboplatin) and  Taxol (paclitaxel). Positive results

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *